(Building 37, Room 5108). 5.3.3 Tumo r Biopsy Collection Tissue biopsies will be encouraged but done strictly on a voluntary basis. Standard techniques will be used for pre -treatment and post -treatment percutaneous biopsies which may include CT, cone beam CT, ultrasound, or fusion guided biopsy. When clinically feasible and judged minimal risk by Interventional Radiology, the same total number biopsies will be prospectively acquired from areas of tumor that may exhibit imaging features of higher or lower cellularity, such as higher PET scan activity, or evidence solid features or viability on CT scan. This will allow biopsy specimens t o be marked as “high imaging cellularity” or “low imaging cellularity”, which could enhance the ability to obtain quality tissue biomarkers, immunohistochemistry or mRNA, and could facilitate the identification of reliable biomarkers for response. Biopsies will be obtained from primary tumor sites and metastatic sites (if applicable) . No more than 4 cores may be obtained per site. Half of the biopsy specimen will be used for immunohistochemistry (IHC) analysis . The other half will be used for gene expres sion analysis. Archival tissue from all subjects will be obtained if possible, with exception for subjects who agree to the optional tumor biopsy at screening do will not need archival tissue obtained . Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 49 Processing and Storage The fixed tissue samples that will be used for IHC analysis will be processed and embedded in paraffin. Tissue blocks will be made from the paraffin-embedded tissue.